MX2019002526A - Agente terapeutico para trastornos de queratoconjuntivitis. - Google Patents

Agente terapeutico para trastornos de queratoconjuntivitis.

Info

Publication number
MX2019002526A
MX2019002526A MX2019002526A MX2019002526A MX2019002526A MX 2019002526 A MX2019002526 A MX 2019002526A MX 2019002526 A MX2019002526 A MX 2019002526A MX 2019002526 A MX2019002526 A MX 2019002526A MX 2019002526 A MX2019002526 A MX 2019002526A
Authority
MX
Mexico
Prior art keywords
therapeutic agent
corneal
disorders
keratoconjunctive
keratitis
Prior art date
Application number
MX2019002526A
Other languages
English (en)
Inventor
Kimura Kazuhiro
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50684334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019002526(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of MX2019002526A publication Critical patent/MX2019002526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)

Abstract

La invención actual aborda el problema de proporcionar un agente terapéutico novedoso para trastornos de queratoconjuntivitis. Como un medio para solucionar el problema, se proporciona un agente terapéutico para trastornos de queratoconjuntivitis que contiene un agonista RAR? como un ingrediente activo. El agente terapéutico exhibe un efecto de aminoración excelente en un modelo de trastorno de queratoconjuntivitis, y por lo tanto es útil como un agente terapéutico para trastornos de queratoconjuntivitis tales como úlcera de córnea, abrasión epitelial de córnea, queratitis, ojo seco, conjuntivitis, queratitis superficial crónica, erosión de córnea, trastornos persistentes de córnea, queratopatía punteada superficial, defectos epiteliales de la córnea, defectos epiteliales conjuntivales, queratoconjuntivitis seca, queratoconjuntivitis límbica superior, queratoconjuntivitis filamentosa, queratitis infecciosa, queratitis no infecciosa, conjuntivitis infecciosa y conjuntivitis no infecciosa. El agente terapéutico también es útil como un agente terapéutico para cicatrizado de córnea y cicatrizado conjuntival, ambos asociados con trastornos de queratoconjuntivitis.
MX2019002526A 2012-11-08 2015-05-08 Agente terapeutico para trastornos de queratoconjuntivitis. MX2019002526A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012246373 2012-11-08

Publications (1)

Publication Number Publication Date
MX2019002526A true MX2019002526A (es) 2019-07-15

Family

ID=50684334

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005842A MX363111B (es) 2012-11-08 2013-11-07 Agente terapeutico para trastornos de queratoconjuntivitis.
MX2019002526A MX2019002526A (es) 2012-11-08 2015-05-08 Agente terapeutico para trastornos de queratoconjuntivitis.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015005842A MX363111B (es) 2012-11-08 2013-11-07 Agente terapeutico para trastornos de queratoconjuntivitis.

Country Status (17)

Country Link
US (6) US9492431B2 (es)
EP (1) EP2918290B1 (es)
JP (3) JP6254529B2 (es)
KR (1) KR102173932B1 (es)
CN (2) CN105188753B (es)
AU (2) AU2013342882B2 (es)
BR (1) BR112015010428B1 (es)
CA (1) CA2890424C (es)
CL (2) CL2015001225A1 (es)
ES (1) ES2834111T3 (es)
HK (1) HK1219224A1 (es)
MX (2) MX363111B (es)
NZ (1) NZ708756A (es)
RU (1) RU2659203C2 (es)
SG (2) SG10201704687YA (es)
WO (1) WO2014073209A1 (es)
ZA (1) ZA201504065B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014073209A1 (ja) 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
MX362239B (es) 2013-05-22 2019-01-09 Univ Yamaguchi Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.
IL295440A (en) 2016-06-08 2022-10-01 Clementia Pharmaceuticals Inc Methods for the treatment of heterotopic aggravation
EA039050B1 (ru) 2016-11-16 2021-11-26 Клементиа Фармасьютикалс Инк. Способы лечения множественного остеохондроматоза (мо)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015902A1 (en) 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
EP1265637A2 (en) 2000-03-14 2002-12-18 The University Of Western Ontario Compositions and methods for affecting osteogenesis
DK1324970T3 (da) * 2000-10-02 2009-01-05 Hoffmann La Roche Retinoider til behandling af emfysem
CN1283621C (zh) 2001-09-18 2006-11-08 霍夫曼-拉罗奇有限公司 烷基脲的类维生素a激动剂ⅰ
CN1301968C (zh) 2001-09-18 2007-02-28 霍夫曼-拉罗奇有限公司 取代的脲的类维生素a激动剂ⅱ
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
AU2006227623B2 (en) 2005-03-17 2011-10-20 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
US20090281184A1 (en) 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
AU2007233868A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
TR201819157T4 (tr) 2006-05-16 2019-01-21 Io Therapeutics Llc Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP2009235031A (ja) * 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
EP2379174A4 (en) 2008-12-18 2012-11-14 Astrazeneca Ab PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
US20120121546A1 (en) 2009-02-05 2012-05-17 Vishal Bhasin Method of Producing Progenitor Cells from Differentiated Cells
DK2613776T3 (da) 2010-09-01 2020-10-19 Univ Jefferson Sammensætning og fremgangsmåde til muskelreparation og -regenerering
CA2812952A1 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
WO2014073209A1 (ja) * 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
MX362239B (es) 2013-05-22 2019-01-09 Univ Yamaguchi Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.

Also Published As

Publication number Publication date
EP2918290A4 (en) 2016-05-18
CN105188753A (zh) 2015-12-23
AU2013342882B2 (en) 2018-05-17
MX2015005842A (es) 2016-01-20
SG11201503612QA (en) 2015-06-29
WO2014073209A1 (ja) 2014-05-15
JP2018030887A (ja) 2018-03-01
JP2019069992A (ja) 2019-05-09
ZA201504065B (en) 2016-11-30
JP6462836B2 (ja) 2019-01-30
EP2918290B1 (en) 2020-09-02
US20200345695A1 (en) 2020-11-05
US20170065562A1 (en) 2017-03-09
CN109589324A (zh) 2019-04-09
CA2890424A1 (en) 2014-05-15
RU2015121628A (ru) 2016-12-27
CA2890424C (en) 2020-11-17
US10537556B2 (en) 2020-01-21
US11471440B2 (en) 2022-10-18
HK1219224A1 (zh) 2017-03-31
CN109589324B (zh) 2022-06-14
AU2018217197B2 (en) 2020-03-05
BR112015010428A2 (pt) 2017-07-11
KR20150082326A (ko) 2015-07-15
JPWO2014073209A1 (ja) 2016-09-08
US20180000782A1 (en) 2018-01-04
JP6254529B2 (ja) 2017-12-27
SG10201704687YA (en) 2017-07-28
AU2013342882A1 (en) 2015-06-11
US10016395B2 (en) 2018-07-10
KR102173932B1 (ko) 2020-11-04
CN105188753B (zh) 2018-12-18
US20190134002A1 (en) 2019-05-09
US9492431B2 (en) 2016-11-15
AU2018217197A1 (en) 2018-08-30
ES2834111T3 (es) 2021-06-16
RU2659203C2 (ru) 2018-06-28
CL2015001225A1 (es) 2016-03-04
US20230255937A1 (en) 2023-08-17
US9750721B2 (en) 2017-09-05
JP6744389B2 (ja) 2020-08-19
BR112015010428B1 (pt) 2020-04-22
EP2918290A1 (en) 2015-09-16
NZ708756A (en) 2019-07-26
CL2018001915A1 (es) 2018-08-31
US20150290172A1 (en) 2015-10-15
MX363111B (es) 2019-03-08

Similar Documents

Publication Publication Date Title
MX2019002526A (es) Agente terapeutico para trastornos de queratoconjuntivitis.
MX2018000745A (es) Metodos para tratar trastornos del desarrollo con gaboxadol.
BR112015019794A2 (pt) composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
UY36275A (es) Compuestos aminopirimidinilo
MY191381A (en) Novel amino pyrimidine derivatives
CL2015001358A1 (es) Potenciadores del cftr deuterados
EA033689B9 (ru) Ингибиторы g12c kras
MX363182B (es) Composiciones que comprenden mezclas de alcanos semifluorados.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.
CL2013003400A1 (es) Forma cristalina 2 de ciclosporina a e hidrato no-estequiométrico de la misma; composición farmacéutica que la comprende, útil para tratar un estado de ojo seco acuoso deficiente, uveitis, endoftalmitis facoanafiláctica y queratoconjuntivitis seca.
WO2012121977A3 (en) Dodecafluoropentane emulsion as a stroke and ischemia therapy
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
GEP20207098B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
TN2013000373A1 (en) Pharmaceutical formulation comprising inositol
MY166314A (en) Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
WO2015195684A3 (en) Small molecule anti-scarring agents
WO2017218942A8 (en) COMPOSITIONS AND METHODS FOR TREATING DRY SYNDROME AND OTHER NON-KERATINIZED EPITHELIAL SURFACES WITH TRAUMA OCCURRENCE
RU2019104946A (ru) Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
PH12016500980B1 (en) Amide derivatives for gpr119 agonist
IN2014DN08296A (es)

Legal Events

Date Code Title Description
FG Grant or registration